D W Hommes

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
    Daan Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Gastroenterology 122:7-14. 2002
  2. ncbi Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
    D W Hommes
    Department Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Gut 55:1131-7. 2006
  3. ncbi The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research
    Daniel W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Inflamm Bowel Dis 10:245-50. 2004
  4. ncbi Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease
    D W Hommes
    Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Curr Opin Clin Nutr Metab Care 3:191-5. 2000
  5. ncbi Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital
    Daan W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Center, C2 116, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Inflamm Bowel Dis 8:81-6. 2002
  6. ncbi Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets
    D W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Gut 52:144-51. 2003
  7. ncbi Infliximab therapy in Crohn's disease: safety issues
    D W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Neth J Med 61:100-4. 2003
  8. ncbi Immunomodulation of mucosal inflammation
    Daan W Hommes
    Department of Gastroenterology and Hepatology, C2-111 Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Pediatr Gastroenterol Nutr 39:S744-5. 2004
  9. ncbi Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease
    M W M D Lutgens
    Department of Gastroenterology and Hepatology, University Medical Center, 3584 CX Utrecht, The Netherlands
    Br J Cancer 101:1671-5. 2009
  10. ncbi Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort
    R K Weersma
    Department of Gastroenterology and Hepatology, University Medical Center Groningen and University of Groningen, P O Box 30001, 9700 RB Groningen, The Netherlands
    Gut 58:388-95. 2009

Collaborators

Detail Information

Publications42

  1. ncbi Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease
    Daan Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Gastroenterology 122:7-14. 2002
    ..We investigated if inhibition of mitogen-activated protein kinases (MAPKs) was beneficial in Crohn's disease...
  2. ncbi Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease
    D W Hommes
    Department Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Gut 55:1131-7. 2006
    ..We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe CD...
  3. ncbi The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research
    Daniel W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Inflamm Bowel Dis 10:245-50. 2004
    ..We identified and analyzed more than 30 case reports and 9 case series. Based on these results, we propose a model for viral replication during inflammation and provide recommendations for future research...
  4. ncbi Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease
    D W Hommes
    Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Curr Opin Clin Nutr Metab Care 3:191-5. 2000
    ....
  5. ncbi Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital
    Daan W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Center, C2 116, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Inflamm Bowel Dis 8:81-6. 2002
    ..Higher response rates were seen with methotrexate as concomitant medication...
  6. ncbi Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets
    D W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
    Gut 52:144-51. 2003
    ..Here, our current understanding of the MAP kinase pathway is reviewed, as well as recent advances in the design of novel agents that are able to modulate the activity of these signalling cascades...
  7. ncbi Infliximab therapy in Crohn's disease: safety issues
    D W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Neth J Med 61:100-4. 2003
    ..This review discusses some immunological aspects that are relevant for infliximab therapy and provides guidelines for daily practice...
  8. ncbi Immunomodulation of mucosal inflammation
    Daan W Hommes
    Department of Gastroenterology and Hepatology, C2-111 Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Pediatr Gastroenterol Nutr 39:S744-5. 2004
  9. ncbi Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease
    M W M D Lutgens
    Department of Gastroenterology and Hepatology, University Medical Center, 3584 CX Utrecht, The Netherlands
    Br J Cancer 101:1671-5. 2009
    ..Colonoscopic surveillance provides the best practical means for preventing colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients. Strong evidence for improved survival from surveillance programmes is sparse...
  10. ncbi Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort
    R K Weersma
    Department of Gastroenterology and Hepatology, University Medical Center Groningen and University of Groningen, P O Box 30001, 9700 RB Groningen, The Netherlands
    Gut 58:388-95. 2009
    ..We assessed the risk for both the development and severity of the disease by combining information from genetic variants associated with inflammatory bowel disease (IBD)...
  11. ncbi More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis
    M M H Claessen
    Department of Gastroenterology and Hepatology, University Medical Center Utrecht, The Netherlands
    Inflamm Bowel Dis 15:1331-6. 2009
    ....
  12. ncbi Therapeutic modulation of signal transduction pathways
    M Lowenberg
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Inflamm Bowel Dis 10:S52-7. 2004
  13. ncbi High frequency of early colorectal cancer in inflammatory bowel disease
    M W M D Lutgens
    Department of Gastroenterology and Hepatology, University Medical Center, Utrecht, The Netherlands
    Gut 57:1246-51. 2008
    ..Our aim was to assess the time interval between onset of inflammatory bowel disease (IBD) and colorectal carcinoma (CRC), and subsequently evaluate how many patients developed cancer before their surveillance was recommended to commence...
  14. ncbi Guidelines for treatment with infliximab for Crohn's disease
    D W Hommes
    Academic Medical Centre, Amsterdam, The Netherlands
    Neth J Med 64:219-29. 2006
    ..Infections and most specifically tuberculosis need to be ruled out before infliximab is administered. Up to now, there are no indications for a connection between an increased risk for malignancies and treatment with infliximab...
  15. ncbi Modulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseases
    K F Bruin
    Centre for Haemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    Eur J Gastroenterol Hepatol 7:791-5. 1995
    ....
  16. ncbi Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis
    E Dekker
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Endoscopy 39:216-21. 2007
    ..The aim of this study was to compare the accuracy of narrow-band imaging (NBI), a new imaging technique, with standard colonoscopy for the detection of neoplasia in patients with longstanding ulcerative colitis...
  17. ncbi New cytokine therapeutics for inflammatory bowel disease
    P C F Stokkers
    Department of Gastroenterology and Hepatology, C2 111, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Cytokine 28:167-73. 2004
    ..Antisense therapy targeting lymphocyte migration has also been tested in IBD. Finally, the conventional drug thalidomide and possibly MAP-kinase inhibitors may become novel treatment entities for IBD...
  18. ncbi Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease
    L P L Gilissen
    Department of Gastroenterology and Hepatology, University Hospital Maastricht azM, P Debyelaan 25, P O Box 5800, 6202 AZ Maastricht, The Netherlands
    Dig Liver Dis 39:182-6. 2007
    ..Apparently, 6-methylmercaptopurine ribonucleotides metabolites can cause pancytopenia, as was already known for 6-thioguanine nucleotides...
  19. ncbi Pharmacogenetics of thiopurine therapy in paediatric IBD patients
    L de Ridder
    Department of Paediatric Gastroenterology, Emma Children s Hospital Academic Medical Center, Amsterdam, The Netherlands
    Aliment Pharmacol Ther 23:1137-41. 2006
    ..The occurrence and type of adverse events to azathioprine may be related to thiopurine S-methyltransferase (TPMT) enzyme activity and to inosine triphophate pyrophosphatase (ITPase) deficiency...
  20. ncbi Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients
    L J A C Hawinkels
    Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands
    Br J Cancer 97:398-404. 2007
    ..In conclusion we have shown localisation and clinical relevance of TGF-beta1 activity levels in gastric cancer...
  21. ncbi Recurrence after segmental resection for colonic Crohn's disease
    S W Polle
    Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands
    Br J Surg 92:1143-9. 2005
    ..Of the 30 patients who had re-resection, 24 finally had a stoma. CONCLUSION: Segmental resection for Crohn's colitis is justified. Recurrence is more frequent in women and in those with a history of perianal disease...
  22. ncbi Muramyl dipeptide-induced differential gene expression in NOD2 mutant and wild-type Crohn's disease patient-derived dendritic cells
    Zuzana Zelinkova
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Inflamm Bowel Dis 14:186-94. 2008
    ..To study the mechanism of CD resulting from NOD2 mutations, we analyzed NOD2-dependent whole-genome expression profiles of patient-derived antigen-presenting cells...
  23. ncbi Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands
    Mark Lowenberg
    Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Steroids 73:1025-9. 2008
    ..As a consequence, membrane-linked GC receptors might be a potential candidate target for GC therapy. The ultimate goal is to convert these molecular insights into new GC receptor modulators with an improved therapeutic index...
  24. ncbi Feasibility of evaluating Crohn's disease activity at 3.0 Tesla
    Karin van Gemert-Horsthuis
    Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
    J Magn Reson Imaging 24:340-8. 2006
    ..To determine whether abdominal 3.0T MRI can be used for evaluation of Crohn's disease (CD) compared with ileocolonoscopy (CS), and to determine patient preference for MRI as opposed to CS...
  25. ncbi Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells
    Astrid J van Beelen
    Department of Cell Biology and Histology, Academic Medical Centre of the University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
    Immunity 27:660-9. 2007
    ..Thus, antibacterial Th17-mediated immunity in humans is orchestrated by DCs upon sensing bacterial NOD2-ligand MDP...
  26. ncbi Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease
    Jasper Florie
    Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 3:1221-8. 2005
    ..The purpose of this study was to assess the value of MRI in measuring disease activity in CD patients in comparison with ileocolonoscopy...
  27. ncbi Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
    Cindy Stahn
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Schumannstrasse 20 21, 10117 Berlin, Germany
    Mol Cell Endocrinol 275:71-8. 2007
    ..Here, we review the above-mentioned mechanisms of glucocorticoid action and give particular attention to the development of optimized glucocorticoids and SEGRAs...
  28. ncbi Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease
    Martin J W Meijer
    Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
    World J Gastroenterol 13:2960-6. 2007
    ....
  29. ncbi Pharmacogenomics in inflammatory bowel disease
    Laurence J Egan
    Department of Pharmacology, National University of Ireland, Galway, Ireland
    Clin Gastroenterol Hepatol 4:21-8. 2006
    ..If this promise can be realized, pharmacogenomics will deliver the opportunity for personalized medicine...
  30. ncbi Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression
    Mark Lowenberg
    Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef, Amsterdam, The Netherlands
    Trends Mol Med 13:158-63. 2007
    ..Drugs that selectively target membrane-bound glucocorticoid receptors might represent a novel immunosuppressive approach...
  31. ncbi Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease
    Anje A te Velde
    Center of Experimental and Molecular Medicine, AMC, Amsterdam, The Netherlands
    Inflamm Bowel Dis 13:325-30. 2007
    ..Mouse models of inflammatory bowel diseases (IBD) are used to unravel the pathophysiology of IBD and to study new treatment modalities, but their relationship to Crohn's disease (CD) or ulcerative colitis (UC) is speculative...
  32. ncbi Critical appraisal of the current practice in murine TNBS-induced colitis
    Anje A te Velde
    Centre for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Inflamm Bowel Dis 12:995-9. 2006
    ..We compare the different protocols, discuss the mechanism of disease and give recommendations for the future use of the model...
  33. ncbi Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease
    Pieter C F Stokkers
    Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands
    Scand J Gastroenterol 41:200-4. 2006
    ..We investigated whether intravenous pamidronate is a safe and effective treatment...
  34. ncbi Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN
    Mark Lowenberg
    Laboratory of Experimental Internal Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    EMBO Rep 7:1023-9. 2006
    ..These observations support a model for nongenomic GC-induced immunosuppression on the basis of dissolution of membrane-bound GC-receptor multiprotein complexes after GC-receptor ligation...
  35. ncbi Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy
    Luc J J Derijks
    Department of Clinical Pharmacy, Maasland Hospital Sittard, St Laurentius Hospital, Roermond, The Netherlands
    Ther Drug Monit 26:311-8. 2004
    ..0 (CI95% 1.7-92.3) of developing leukopenia. A 6-MMPR/6-TGN ratio less than 11 was associated with therapeutic efficacy. Based on this pharmacokinetic analysis, therapeutic drug monitoring is essential for rational 6-MP dosing...
  36. ncbi Endoscopy in inflammatory bowel diseases
    Daniel W Hommes
    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
    Gastroenterology 126:1561-73. 2004
    ..Here we propose guidelines for endoscopy in inflammatory bowel disease, and review all currently available endoscopic techniques relevant to the proper treatment of IBD patients...
  37. ncbi Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Center, PO Box 7777, 5500 MB Veldhoven, The Netherlands
    Curr Gastroenterol Rep 8:89-92. 2006
  38. ncbi Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease
    Luc J J Derijks
    Department of Clinical Pharmacy, Maxima Medical Center, Veldhoven, The Netherlands
    Ther Drug Monit 28:45-50. 2006
    ..In our population, we could not demonstrate a clear relationship between 6-TGN concentrations on one hand and toxicity and efficacy on the other, as exist in AZA- and 6-MP-treated patients...
  39. ncbi The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway
    Liudmila L Kodach
    Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Gastroenterology 133:1272-81. 2007
    ..Statins induce bone morphogenetic protein (BMP) expression in bone cells. We have previously shown that BMPs act as tumor suppressors in CRC. We hypothesized that the action of statins in CRC involves the induction of BMPs...
  40. ncbi Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice
    Sylvia A Bleuming
    Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Cancer Res 67:8149-55. 2007
    ..Our data show that BMP signaling through Bmpr1a suppresses tumorigenesis at gastric epithelial junctional zones that are distinct from the adjacent gastric epithelium in both cellular differentiation and proliferation...
  41. ncbi Biologics in Crohn's disease: searching indicators for outcome
    C Janneke van der Woude
    Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
    Expert Opin Biol Ther 7:1233-43. 2007
    ..This review presents biologics in Crohn's disease focusing on efficacy, steroid sparing, mucosal healing and safety, including immunogenicity...
  42. ncbi A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease
    Henri Braat
    Department of Experimental Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Clin Gastroenterol Hepatol 4:754-9. 2006
    ..This novel strategy avoids systemic side effects and is biologically contained; therefore it is suitable as maintenance treatment for chronic intestinal disease...